09:05 ET - Pfizer winning the bidding war for Metsera should be welcome news for investors despite the higher price, say JPMorgan analysts. Pfizer needed to broaden its drug pipeline and the deal shows its dedication to gaining a share of the obesity treatment market. Metsera's lead GLP-1 asset, MET-097i, has the potential for once-monthly dosing which could give it a "niche role in the rapidly expanding obesity market," the analysts say. Eli Lilly and Novo Nordisk are still likely to remain the dominant players and retain their time-to-market and insurance coverage advantages, but even modest share for MET-097i would create a multi-billion dollar opportunity for Pfizer, the analysts say. (nicholas.miller@wsj.com)

(END) Dow Jones Newswires

November 10, 2025 09:05 ET (14:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.